Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic
Corresponding Author
Sue Pavord
Department of Haematology, Oxford University Hospitals, Oxford, UK
Correspondence: Sue Pavord, Haematology, Oxford University Hospitals, Old Road, Headington, OX3 7LE Oxford, UK.
E-mail: [email protected]
Search for more papers by this authorJecko Thachil
Department of Haematology, Manchester University Foundation Trust, Manchester, UK
Search for more papers by this authorBeverley J. Hunt
Department of Haematology, Guy's and St Thomas' Hospital, London, UK
Search for more papers by this authorMike Murphy
Department of Haematology, John Radcliffe Hospital, NHSBT, Oxford, UK
Search for more papers by this authorGillian Lowe
Department of Haematology, University Hospitals of Birmingham, Birmingham, UK
Search for more papers by this authorMike Laffan
Department of Haematology, Hammersmith Hospital, Du Cane Road, UK
Search for more papers by this authorMike Makris
Department of Haematology, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Search for more papers by this authorAdrian C. Newland
Department of Haematology, Barts and the London School of Medicine and Dentistry, London, UK
Search for more papers by this authorDrew Provan
Department of Haematology, Queen Mary University of London, Bart's and The London School of Medicine and Dentistry, Institute of Cell and Molecular Science, London, UK
Search for more papers by this authorJohn D. Grainger
Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK
Search for more papers by this authorQuentin A. Hill
Department of Haematology, St James's University Hospital, Leeds, UK
Search for more papers by this authorCorresponding Author
Sue Pavord
Department of Haematology, Oxford University Hospitals, Oxford, UK
Correspondence: Sue Pavord, Haematology, Oxford University Hospitals, Old Road, Headington, OX3 7LE Oxford, UK.
E-mail: [email protected]
Search for more papers by this authorJecko Thachil
Department of Haematology, Manchester University Foundation Trust, Manchester, UK
Search for more papers by this authorBeverley J. Hunt
Department of Haematology, Guy's and St Thomas' Hospital, London, UK
Search for more papers by this authorMike Murphy
Department of Haematology, John Radcliffe Hospital, NHSBT, Oxford, UK
Search for more papers by this authorGillian Lowe
Department of Haematology, University Hospitals of Birmingham, Birmingham, UK
Search for more papers by this authorMike Laffan
Department of Haematology, Hammersmith Hospital, Du Cane Road, UK
Search for more papers by this authorMike Makris
Department of Haematology, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
Search for more papers by this authorAdrian C. Newland
Department of Haematology, Barts and the London School of Medicine and Dentistry, London, UK
Search for more papers by this authorDrew Provan
Department of Haematology, Queen Mary University of London, Bart's and The London School of Medicine and Dentistry, Institute of Cell and Molecular Science, London, UK
Search for more papers by this authorJohn D. Grainger
Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK
Search for more papers by this authorQuentin A. Hill
Department of Haematology, St James's University Hospital, Leeds, UK
Search for more papers by this authorSummary
This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on immune thrombocytopenia (ITP), during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.
References
- 1Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intens Care Med. 2020; 46: 854–87. https://doi.org/10.1007/s00134-020-06022-5
- 2Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018; 197: 757–67.
- 3Assinger A. Platelets and infection – an emerging role of platelets in viral infection. Front Immunol. 2014; 5: 649.
- 4Bangash M, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020; 5: 529–30.https://doi.org/10.1016/S2468-1253(20)30084-4
- 5Catala-Lopez F, Corrales I, Martin-Serrano G, Tobias A, Calvo G. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin. 2012; 139: 421–9.
- 6Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017; 102: 1342–51.
- 7D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplant. 2020. https://doi.org/10.1002/lt.25756
- 8Delaney JW, Pinto R, Long J, Lamontagne F, Adhikari NK, Kumar A, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care. 2016; 20: 75.
- 9Fox SE, Akmatbekov A, Harbert J, Li G, Brown Q, Vander Heide RS. Pulmonary and cardiac pathology in COVID-19: The First Autopsy Series from New Orleans. medRxiv. 2020. https://doi.org/10.1101/2020.04.06.20050575
- 10Garabet L, Ghanima W, Hellum M, Sandset PM, Bussel JB, Tran H, et al. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists. Platelets. 2020; 31: 322–8.
- 11Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al., et al.; for the China Medical Treatment Expert Group for COVID-19. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382: 1708–20.
- 12Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2009567
- 13Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
- 14Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. 2020. https://b-s-h.org.uk/media/18171/th-and-covid-25-march-2020-final.pdf
- 15Ji HL, Zhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020; 100: 1065–75.
- 16Klok FA, Kruipb MJHA, van der Meer NJM, Arbousd MS, Gommerse DAMPJ, Kantf KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19.Thromb Res. 2020. https://doi.org/10.1016/j.thromres.2020.04.013
- 17Kolb-Mäurer A, Goebel W. Susceptibility of hematopoietic stem cells to pathogens: role in virus/bacteria tropism and pathogenesis. FEMS Microbiol Lett. 2003; 226: 203–7.
- 18Kuter, DJ, Newland, A, Chong, BH, Rodeghiero, F, Romero, M, Pabinger, I, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019; 185: 503–13.
- 19Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019; 24: 2. https://doi.org/10.1002/14651858.CD010406.pub3
- 20Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020; 506: 145–8. https://doi.org/10.1016/j.cca.2020.03.022
- 21Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MC, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14888
- 22Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020; 79: 667–8.
- 23Ness T. Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients (TCInpatient). 2020. ClinicalTrials.gov: NCT04338126.
- 24Nijsten MW, ten Duis H-J, Zijlstra J, Porte RJ, Zwaveling JH, Paling JC, et al. Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med. 2000; 28: 3843–6.
- 25 PROMACTA®. (eltrombopag) tablets, for oral use; PROMACTA® (eltrombopag) for oral suspension [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.
- 26Provan D, Arnold D, Bussell J, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019; 3: 3780–817.
- 27 Revolade. Revolade (olamine) [summary of product characteristics]. Dublin, Ireland: Novartis Europharm Limited; 2018.
- 28Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014; 12: 1266–73.
- 29Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013; 27: 171–8.
- 30Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020.https://doi.org/10.1111/jth.14817.
- 31Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14879
- 32Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and antithrombotic treatment in Coronavirus 2019: a new challenge. Thromb Haemost. 2020. https://doi.org/10.1055/s-0040-1710317
- 33Wang T, Chen R, Liu C, Chen R, Liu C, Liang W, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020; 7: E362–E363. https://doi.org/10.1016/S2352-3026(20)30109-5
- 34Wong R, Saleh M, Khelif A, Salama A, Portella MSO, Burgess P, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017; 130: 2527–36. https://doi.org/10.1182/blood-2017-04-748707
- 35 World Health Organisation. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance 13 March 2020.
- 36Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.03.044
- 37Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14848
- 38Zulfiqar A-A, Lorenzo-Villalba N. Immune thrombocytopenia in a patient with COVID-19. N Engl J Med. 2020; 382: e43.
Citing Literature
